Biocardia stock

BioCardia, Inc. (BCDA) has been upgraded to a

The latest update sent BioCardia’s stock down around 20% to 62 cents in premarket trading, adding to losses that have seen the share price slide by more than 60% in six months.Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...

Did you know?

The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...$1.0401 0.6411 [160.68%] Last update: 4:12PM (Delayed 15-Minutes) Get Real Time Here $1.0401 0 [0.00%] Profile News Analyst Ratings Guidance Dividends …Latest BioCardia Inc Stock News. As of October 04, 2023, BioCardia Inc had a $8.9 million market capitalization, putting it in the 12th percentile of companies in the Biotechnology & Medical Research industry. BioCardia Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months.Nov 8, 2023 · BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...The upgrade of BioCardia, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term ...2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 08 NovFind the latest 23andMe Holding Co. (ME) stock quote, history, news and other vital information to help you with your stock trading and investing.6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ...Analysts who follow BioCardia Inc on average expect it to increase 1150.00% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BioCardia Inc an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver.The estimated Net Worth of Peter Altman is at least $913 millier dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $235,166 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer et Director at BioCardia.Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth 4,096$ on 5 November 2018.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Additional factors that could materially affect actual results can bNov 14, 2023 · BioCardia ( NASDAQ: BCDA) sh The Wall Street analyst predicted. that Biocardia's share price could reach $4.00 by Nov 14, 2024. The average Biocardia stock price prediction forecasts a potential upside of 495.24% from the current BCDA share price of $0.67. A high-level overview of BioCardia, Inc. (BCDA) stock. A. BioCardia ( BCDA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $357K, which beat ... Simon Stertzer owns over 166,666 units of BioCard

Biocardia trades on the NASDAQ stock market under the symbol BCDA. What is Biocardia stock price doing today? As of November 29, 2023, BCDA stock price declined to $0.68 with 702,007 million shares trading.Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comNov 30, 2023 · BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. A new COVID variant, HV.1, is now dominant. These are its most common symptoms. Deer hunting is dying. That should worry you even if you don't hunt. The FDA approved BioCardia Inc's (NASDAQ: BCDA ...

Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26.…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCa. Possible cause: Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the de.

About the BioCardia Inc. stock forecast. As of 2023 November 17, Friday current price of BCDA stock is 0.790$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. BioCardia stock price has been showing a declining tendency so we believe that similar market segments were not very …Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $5,711 on 13 January 2018.14,277 units of BCDA stock worth $5,711 on 13 January 2018.BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26.

Sep 6, 2023 · SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... 8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.

The three major U.S. stock exchanges are the New York BioCardia has received a go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed to help rescue patients from heart failure. The green light clears ...Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month. BioCardia Stock Price, News & Analysis (NASDAQ:BAbout the BioCardia Inc. stock forecast. As of 2023 BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA. BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8- BioCardia Inc ( BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02. BCDA's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 123 out of 146 industries, the …May 30, 2023 · BioCardia has made significant progress in the development of its therapeutic candidates BCDA-01 and BCDA-02. Check out my recommendation on BCDA stock. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardiaBioCardia, Inc. (BCDA) Reports Q3 Loss, TopsWhat are the best stocks to buy? Learn how you can m You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.16 Nov 2023 ... BioCardia develops cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Stock BCDA logo. BioCardia ... Nov 14, 2023 · BioCardia announces that BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular ... BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K[The estimated Net Worth of Richard M Krasno is at least $410 milBioCardia Inc. analyst ratings, historical stock p Richard Krasno, Ph.D. was appointed to our board of directors in October 2016. Dr. Krasno has served as a director of OPKO Health, Inc. since 2017. Dr. Krasno previously served as a director on the board of Ladenburg Thalmann from 2006 until 2020 and Castle Brands, Inc. from 2014 until 2019. Dr.Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled ...